Stockscreener 앱 받기
18.06
4.80%
-0.91
Nurix Therapeutics Inc 주식(NRIX)의 최신 뉴스
Trading Systems Reacting to (NRIX) Volatility - Stock Traders Daily
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Is It Too Late to Sell Shiva Texyarn LimitedTechnical Breakout Signals & Discover Top Gainers in Every Sector - earlytimes.in
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge - GlobeNewswire
(NRIX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Certain Pre-funded Warrants of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025. - marketscreener.com
Certain Restricted Stock Units of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025. - marketscreener.com
Certain Stock Options of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025. - marketscreener.com
Certain Common Stock of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025. - marketscreener.com
Does Strong Early Waldenström Data Redraw The Bull Case For Nurix Therapeutics’ Degrader Platform (NRIX)? - Yahoo Finance
Wells Fargo Reaffirms a Buy Rating on Nurix Therapeutics (NRIX), Sets a $30 PT - Insider Monkey
Nurix Therapeutics (NRIX): Revisiting Valuation After a 120% Three-Month Share Price Surge - Yahoo Finance
Should I hold or sell Nurix Therapeutics Inc. stock in 20252025 Geopolitical Influence & AI Forecasted Stock Moves - Улправда
Stock Analysis: Is Nurix Therapeutics Inc. stock a defensive play in 2025Quarterly Performance Summary & AI Forecasted Entry and Exit Points - Улправда
12 Small Cap Stocks to Buy with Huge Upside Potential - Insider Monkey
Does New NX-5948 Phase 2 Dose Selection Change The Bull Case For Nurix Therapeutics (NRIX)? - simplywall.st
Is Nurix Therapeutics Inc. stock a defensive play in 2025Index Update & Stepwise Entry/Exit Trade Alerts - Улправда
Will Nurix Therapeutics Inc. stock gain from lower inflationEarnings Trend Report & Reliable Price Breakout Alerts - Улправда
Sell Signal: Is Nurix Therapeutics Inc. stock a defensive play in 2025 - Улправда
Why Nurix Therapeutics Inc. stock appeals to analysts2025 Market Overview & Pattern Based Trade Signal System - ulpravda.ru
Nurix Therapeutics Chief Legal Officer Sells Shares - TradingView — Track All Markets
Officer Ring Sells 3,760 ($67.3K) Of Nurix Therapeutics Inc [NRIX] - TradingView — Track All Markets
Nurix Therapeutics (NRIX) Chief Legal Officer reports option exercise and stock sales - Stock Titan
Why Nurix Therapeutics Inc. stock could outperform in 2025Trade Risk Assessment & Stepwise Swing Trade Plans - Улправда
Institution Moves: Why Nurix Therapeutics Inc. stock appeals to analystsMarket Sentiment Summary & Fast Entry Momentum Trade Alerts - Улправда
Nurix Therapeutics (NASDAQ:NRIX) Trading Down 4%Here's What Happened - MarketBeat
Nurix Therapeutics Advances Study for NX-5948 in CLL and SLL Patients - TipRanks
Nurix Therapeutics (NRIX) Receives a Buy from Wells Fargo - The Globe and Mail
Wells Fargo Raises Price Target for Nurix Therapeutics (NRIX) to $30 | NRIX Stock News - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Given New $30.00 Price Target at Wells Fargo & Company - MarketBeat
Cathie Wood Sells $40M in Tesla, Keeps Cutting Iridium, and Adds Nurix: What ARK Invest’s Latest Trades Signal on Dec. 15, 2025 - ts2.tech
Nurix Therapeutics, Inc. $NRIX Shares Purchased by Nikko Asset Management Americas Inc. - MarketBeat
Redmile Group LLC Lowers Stake in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Optimistic Investors Push Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Up 48% But Growth Is Lacking - 富途牛牛
Nurix prices 24.5M shares at $10.21 in underwritten registered offering - MSN
Nurix Therapeutics price target raised to $31 from $28 at HC Wainwright - MSN
Cathie Wood Reduces Iridium Holdings While Adding Biotech Stock Nurix Therapeutics - parameter.io
Why Cathie Wood Just Sold Millions in Iridium and Bought This Biotech Stock - CoinCentral
Cathie Wood’s ARK sells Iridium stock, buys Nurix on Wednesday By Investing.com - Investing.com Nigeria
Cathie Wood’s ARK sells Iridium stock, buys Nurix on Wednesday - Investing.com
What insider trading reveals about Nurix Therapeutics Inc stockMarket Activity Report & Risk Controlled Daily Plans - moha.gov.vn
HC Wainwright & Co. Maintains Nurix Therapeutics (NRIX) Buy Recommendation - Nasdaq
NRIX: Mizuho Raises Price Target, Maintains Outperform Rating | - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Price Target Raised to $30.00 at Mizuho - MarketBeat
Nurix stock price target raised to $31 from $28 at H.C. Wainwright - Investing.com UK
NRIX: HC Wainwright & Co. Raises Price Target for Nurix Therapeu - GuruFocus
Mizuho Adjusts Price Target on Nurix Therapeutics to $30 From $24, Maintains Outperform Rating - marketscreener.com
Mizuho raises Nurix stock price target to $30 on positive CLL data - Investing.com
BTIG Maintains Nurix Therapeutics (NRIX) Buy Recommendation - Nasdaq
Nurix Therapeutics (NASDAQ:NRIX) Shares Down 5.4%Here's Why - MarketBeat
NRIX Analyst Rating Update: BTIG Raises Price Target | NRIX Stoc - GuruFocus
Nurix (NRIX) soars 18.7% on encouraging blood cancer treatment trial - MSN
Nurix (NRIX) Soars 18.7% on Encouraging Blood Cancer Treatment Trial - Insider Monkey
Nurix Therapeutics Reports Promising Data at Hematology Meeting - TipRanks
NRIX: Bexobrutideg achieved a 75% response rate with durable, well-tolerated outcomes in Waldenström macroglobulinemia - TradingView — Track All Markets
Nurix Therapeutics Presents New Clinical Data at ASH Annual Meeting - TradingView — Track All Markets
Nurix reports 75% response rate for bexobrutideg in WM patients By Investing.com - Investing.com Australia
10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs - Insider Monkey
Nurix Therapeutics (NRIX) Stock Soars on ASH 2025 Trial Data: Latest News, Analyst Forecasts and Outlook as of December 8, 2025 - ts2.tech
Nurix Therapeutics (NASDAQ:NRIX) Shares Gap UpTime to Buy? - MarketBeat
Needham Reiterates Nurix Therapeutics (NRIX) Buy Recommendation - Nasdaq
Could This Biotech, Up 35%, Have The Next Dupixent? - Investor's Business Daily
Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg in Waldenström Macroglobulinemia at the 67th American Society of Hematology Annual Meeting and Exposition - Investing News Network
0.57%
자본화:
|
볼륨(24시간):